Hamdan Medical Journal (previously the Journal of Medical Sciences)
|Table of Contents|
Modulation of Serine Proteases-Mediated Platelet Activation
Kahn ML, Nakanishi-Mitsui M, Shapiro MJ, Ishihara H,Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.J Clin Invest 1999; 103: 879-87.
Andersen H, Greenberg DL, Fujikawa K, Xu W,Chung DW, Davie ED. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 1999; 96: 11189-93.
Ramakrishnan V, De Guzman F, Bao M, Hall SW,Leung LL, Phillips DR. A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. Proc Natl Acad Sci USA 2001; 98: 1823-8.
Fabris F, Ahmad S, Cella G, Jeske WP, Walenga JM,Fareed J. Pathophysiology of heparin-induced thrombocytopenia: Clinical and diagnostic implications- A review. Arch Pathol Lab Med 2000; 124:1657-66.
Ahmad S. Heparin-induced thrombocytopenia:Impact of bovine versus porcine heparin in HIT pathogenesis. Front Biosci 2007; 12: 3312-20.
Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74.
Weitz JI, Crowther M. Direct thrombin inhibitors.Thromb Res 2002; 106: V275-V284.
Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin. Am J Cardiol 1998; 82: 12P-18P.
Iqbal O, Ahmad S, Lewis BE, Walenga JM, Rangel Y, Fareed J. Monitoring of argatroban in ARG310 Study: Potential recommendations for its use in interventional cardiology. Clin Appl Thromb Hemost 2002; 8: 217-24.
Ng NJ, Crowther M. New anticoagulants and the management of their bleeding complications.Transfus Altern Transfus Med 2006; 8(Suppl.1): 12-9.
Hursting MJ, Jang IK. Effect of body mass index on argatroban therapy during percutaneous coronary intervention. J Thromb Thrombolysis 2008; 25: 273-9.
Bates SM, Weitz JI. The status of new anticoagulants.Br J Haematol 2006; 134: 3-19.
Murphy GS, Marymont JH. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery. J Cardiothorac Vasc Anesth 2007;21: 113-26.
Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia:Treatment options and special considerations.Pharmacotherapy 2007; 27: 564-87.
Stubbs MT, Bode W. A player of many parts: The spotlight falls on thrombin’s structure. Thromb Res 1993; 69: 1-58.
Ahmad S, Walenga JM, Jeske WP, Cella G, Fareed J. Functional heterogeneity of anti-heparin-platelet factor 4 antibodies: Implications in the pathogenesis of the HIT syndrome. Clin Appl Thromb Hemost 1999; 5(Suppl. 1): S32-S37.
Sheridan D, Carter C, Kelton, JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30.
Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin. Thromb Haemost 1994; 72: 381-6.
Califf RM. A perspective on the regulation of the evaluation of new antithrombotic drugs. Am J Cardiol 1998; 82: 25P-35P.
Banner DW, Hadvary P. Crystallographic analysis at 3.0 Ao resolution of the binding of human thrombin of four active-ite irected inhibitors. J Biol Chem 1991; 266: 20085-91.
Bode W, Turk D, Sturzebecher L. Geometry of binding of the benzamadine- and arginine-based inhibitors N-alpha-(2-naphthyl-sulphonyl-glycyl)-DL-pamidinophenylalanyl-piperidine (NAPAP) and(2R,4R)-4-methyl-1-[N alpha-(3-methyl-1,2,3,4-tetrahydro-8-qyinoline-sulfonyl)-L-arginyl]-2- piperidinecarboxylic acid (MQPA) to human alpha/thrombin: X-ray crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin. Eur J Biochem 1990; 193: 175-81.
Chesebro JH, Zoldhelyi P, Badimon L, Fuster V. Role of trombin in aterial trombosis: Implications for therapy. Thromb Haemost 1991; 66: 1-5.
Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia.Thromb Res 2002; 105: 401-5.
Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P, et al. Use of hirulog in the prevention of venous thrombosis after mjor hip or knee surgery. Circulation 1994; 90: 2385-9.
Chew DP. Bivalirudin, a bivalent, thrombin specificanticoagulant as an alternative to heparin in interventional procedures. Hamostaseologie 2002; 22:60-6.
Fox I, Daeson A, Loynds P, Eisner J, Findlen K, Levin E, et al. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69: 157-63.
Bittl JA, Chaitman FR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142: 952-9.
Seybert, AL. Bivalirudin administration during percutaneous coronary intervention: Emphasis on highrisk patients. Pharmacotherapy 2002; 22: 112S-118S.
Vanholder R, Camez A, Veys N, Van Loo A, Dhondt AM, Ringoir S. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.Thromb Haemost 1997; 77: 650-5.
Serruys PW, Herrman JP, Simon R, Rutsch C, Bode W, Laarman GJ, et al. A Comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty - Helvetica Investigators. N Engl J Med 1995; 333: 757-63.
Grienacher A, Volpel J, Janssens U, Hach-Wunderle V, Kemles-Matthes B, Eichler P, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999; 99: 73-80.
Song X, Huhle G, Wang L, Hoffmann U, Harenberg J. Generation of anti-hirudin antibodies in heparininduced thrombocytopenic patients treated with rhirudin. Circulation 1999; 100: 1528-32.
Eichler P, Friesen H-J, Lubelow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT, and clinical relevance. Blood 2000; 96: 2373-8.
The GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. N Engl J Med 1996; 335:775-82.
Anonymous. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study. Organization to Asses Strategies for Ischemis Syndromes (OASIS) Investigators. Circulation 1997; 96: 769-77.
Anonymous. Effects of recombinant hirudin (lepirudin)compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomized trial. Organization to Assess Strategies for Ischemis Syndromes (OASIS-2) Investigators. Lancet 1999;353 (9151): 429-38